Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Morgan Stanley to launch a new UCITS Fund that offers exposure to Mesirow Financial's Absolute Return Plus Strategy

Monday, February 25, 2013
Opalesque Industry Update: Morgan Stanley today announced the launch of a new fund, the MS Discretionary Plus UCITS Fund, under its FundLogic Alternatives plc umbrella. The fund, which provides exposure to the Mesirow Absolute Return Plus Strategy, is the last in a series of four CTA strategies to be made available in a UCITS format through Morgan Stanley’s partnership with Equinox Fund Management LLC, a U.S.-based multi-manager, specializing in constructing portfolios of multiple Commodity Trading Advisor programs.

This latest addition diversifies Morgan Stanley’s offering of CTA strategies, which currently comprises of a fully transparent and systematic strategy providing exposure to the broad class of managed futures, a short to medium-term pattern recognition program and a long-term trend following program.

“We are proud to provide UCITS investors with access to the Mesirow Absolute Return Plus Strategy, established by Tom C. Willis, an acknowledged market leader in the industry with over 30 years trading experience”, said Alvise Munari, Managing Director and Global Head of Equity Derivatives, Sales and Financial Engineering at Morgan Stanley.

He added: “Mesirow Financial, which has over $65bn of assets under management for all asset classes, has a deep expertise in commodity markets, which has allowed them to deliver innovative solutions for clients worldwide. The Strategy has a large emphasis on commodities, aiming to have a minimum of 75% commodities exposure. It identifies two to three macro themes that are played through futures contracts whilst limiting the amount at risk per trade. This allows consistent returns to be generated, with low volatility in various market environments, with the aim of generating returns in both rising and falling markets.”

Michel Serieyssol, Managing Director at Equinox, commented: “We are delighted by the fourth successful UCITS launch with our partner, Morgan Stanley. Mesirow is a terrific addition to the FundLogic Alternatives Platform, providing investors with a strong diversification tool in Mesirow’s commodity-focused macro approach. Overall, we could not be any happier with the quality and breadth of the CTA offerings we have brought to the market with Morgan Stanley.”

Aaron Ochstein of Mesirow commented: “Morgan Stanley is a market leader in the UCITS Alternatives space, with one of the fastest growing platforms, high-end risk management and operational expertise. We are delighted by this opportunity to partner with both Morgan Stanley and Equinox, in providing access to the Mesirow Absolute Return Plus Strategy to UCITS investors.”

Tom Willis, Senior Strategist and Portfolio Manager of the Mesirow Absolute Plus Strategy said: “As Portfolio Manager, I am excited about the launch of the MS Discretionary Plus Fund, which we believe offers UCITS investors an opportunity to benefit from a strong macro-focused diversification approach. The strength of our Strategy is our seasoned investment team, our disciplined risk management process with an emphasis on capital preservation, combined with a targeted high percentage of profitable trades, on a high win/loss ratio. The Strategy seeks to avoid portfolio concentration on multiple levels, including price, concentration, time, and trade structure, ensuring a strong strategy all around.”

Morgan Stanley

Press Release

BM

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for